Share This Article:

The number of antihypertensive agents simply reflects the grade and the risk of atherosclerosis in patients with type 2 diabetes mellitus

Abstract Full-Text HTML XML Download Download as PDF (Size:337KB) PP. 161-167
DOI: 10.4236/jdm.2013.34025    3,433 Downloads   6,121 Views  

ABSTRACT

Aims: The associations between the number of antihypertensive agents being taken by type 2 diabetic patients and 1) the grade of atherosclerosis according to non-invasive surrogate markers for atherosclerosis and 2) the other risk factor for atherosclerosis, were cross-sectionally investigated. Methods: The association between the blood pressure control and the clinical characteristics was evaluated in 1359 patients with type 2 diabetes mellitus. Results: The number of antihypertensive agents was 1.5 ± 1.4 (2.0 ± 1.2 among the 990 patients with hypertension). The proportion of patients taking no antihypertensive agents was 29%, 22% were taking one, 29% were taking two and 21% of the patients were taking three or more antihypertensive agents. The value of the ankle-brachial pressure index significantly decreased with the increase in the number of antihypertensive agents even if the blood pressure was corrected to the target value. The values of brachial-ankle pulse wave velocity and carotid intima-media thickness were also increased. The prevalence of risk factors for atherosclerosis, such as obesity, hyperlipidemia, chronic kidney disease, hyperuricemia and anemia was significantly elevated with the number of agents. Conclusions: The number of antihypertensive agents simply reflects the grade and risk of atherosclerosis in patients with type 2 diabetes mellitus.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Ito, H. , Abe, M. , Shinozaki, M. , Omoto, T. , Nishio, S. , Furusho, M. , Antoku, S. , Mifune, M. , Togane, M. and Sanaka, T. (2013) The number of antihypertensive agents simply reflects the grade and the risk of atherosclerosis in patients with type 2 diabetes mellitus. Journal of Diabetes Mellitus, 3, 161-167. doi: 10.4236/jdm.2013.34025.

References

[1] Kannel, W.B. (1989) Risk factors in hypertension. Journal of Cardiovascular Pharmacology, 13, S4-S10. http://dx.doi.org/10.1097/00005344-198900131-00003
[2] Iimura, O. (1996) Insulin resistance and hypertension in Japanese. Hypertension Research, 19, S1-S8. http://dx.doi.org/10.1291/hypres.19.SupplementI_S1
[3] UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, 703-713. http://dx.doi.org/ 10.1136/bmj. 317.7160.703
[4] Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. and Neil, H.A. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589. http://dx.doi.org/10.1056/NEJMoa0806470
[5] American Diabetes Association (1989) Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care, 12, 573-579.
[6] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr., J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright Jr., J.T., Roccella, E.J., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252. http://dx.doi.org/10.1161/01.HYP.0000107251. 49515.c2
[7] Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E, Boudier, H.A. and Zanchetti, A., ESH-ESC Task Force on the Management of Arterial Hypertension (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 25, 1105-1187. http://dx.doi.org/10.1097/HJH. 0b013e3281fc975a
[8] Brown, M.J., Castaigne, A., de Leeuw, P.W., Mancia, G., Palmer, C.R., Rosenthal, T. and Ruilope, L.M. (2000) Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension, 35, 1038-1042. http://dx.doi.org/10.1161/01.HYP.35.5.1038
[9] Ito, H., Mifune, M., Abe, M., Oshikiri, K., Antoku, S., Takeuchi, Y., Togane, M., Ando, S. and Tsugami, E. (2012) Hypertension resistant to antihypertensive agents commonly occurs with the progression of diabetic nephropathy in Japanese patients with type 2 diabetes mellitus: A prospective observational study. BMC Nephrology, 13, 48. http://dx.doi.org/10.1186/1471-2369-13-48
[10] Bakris, G.L., Williams, M., Dworkin, L., Elliott, W.J., Epstein, M., Toto, R., Tuttle, K., Douglas, J., Hsueh, W. and Sowers, J. (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. American Journal of Kidney Diseases, 36, 646-661. http://dx.doi.org/10.1053/ ajkd.2000.16225
[11] Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine, 342, 145-153. http://dx.doi.org/10.1056/NEJM200001203420301
[12] ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 288, 2981-2897. http://dx.doi.org/10.1001/jama.288.23.2981
[13] Wing, L.M., Reid, C.M., Ryan, P, Beilin, L.J., Brown, M.A., Jennings, G.L., Johnston, C.I., McNeil, J.J., Macdonald, G.J., Marley, J.E., Morgan, T.O., West, M.J., Second Australian National Blood Pressure Study Group (2003) A comparison of outcomes with angiotensin-converting—Enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal of Medicine, 348, 583-592. http://dx.doi.org/10.1056/NEJMoa021716
[14] Japanese Society of Gout and Nucleic Acid Metabolism (2000) Guideline for the management of hyperuricemia and gout. 2nd Edition, Medical Review Co., Ltd, Tokyo.
[15] Locatelli, F., Covic, A., Eckardt, K.U., Wiecek, A., Vanholder, R., ERA-EDTA ERBP Advisory Board (2009) Anaemia management in patients with chronic kidney disease: A position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation, 24, 348-354. http://dx.doi.org/10.1093/ndt/gfn653
[16] National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. American Journal of Kidney Diseases, 47, S1-S146. http://dx.doi.org/10.1053/S0272-6386(05)01814-7
[17] Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., Hishida, A., Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. American Journal of Kidney Diseases, 53, 982-992. http://dx.doi.org/10.1053/j.ajkd.2008.12.034
[18] Coresh, J., Astor, B.C., Greene, T., Eknoyan, G. and Levey, A.S. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases, 41, 1-12. http://dx.doi.org/10.1053/ajkd. 2003.50007
[19] Levey, A.S., de Jong, P.E., Coresh, J., El Nahas, M., Astor, B.C., Matsushita, K., Gansevoort, R.T., Kasiske, B.L. and Eckardt, K.U. (2011) The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney International, 80, 17-28. http://dx.doi.org/10.1038/ki. 2010.483
[20] Ito, H., Komatsu, Y., Mifune, M., Antoku, S., Ishida, H., Takeuchi, Y. and Togane, M. (2010) The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: A cross-sectional study. Cardiovascular Diabetology, 9, 18. http://dx.doi.org/10.1186/1475-2840-9-18
[21] Obara, T., Ohkubo, T., Kikuya, M., Asayama, K., Metoki, H., Inoue, R., Oikawa, T., Murai, K., Komai, R., Horikawa, T., Hashimoto, J., Totsune, K., Imai, Y., J-HOME Study Group (2006) The current status of home and office blood pressure control among hypertensive patients with diabetes mellitus: The Japan Home Versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Diabetes Research and Clinical Practice, 73, 276-283. http://dx.doi.org/10.1016/j.diabres.2006.01.015
[22] Reaven, G.M. (1988) Role of insulin resistance in human disease. Diabetes, 37, 1595-1607. http://dx.doi.org/10.2337/diabetes.37.12.1595
[23] DeFronzo, R.A. and Ferrannini, E. (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14, 173-194. http://dx.doi.org/10.2337/diacare.14.3.173
[24] Kaplan, N.M. (1989) The deadly quartet: Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Archives of Internal Medicine, 149, 1514-1520. http://dx.doi.org/10.1001/ archinte.1989.00390070054005
[25] Feingold, K.R., Grunfeld, C., Pang, M., Doerrler, W. and Krauss, R.M. (1992) LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 12, 1496-1502. http://dx.doi.org/10.1161/01.ATV.12.12.1496
[26] Ito, H., Takeuchi, Y., Ishida, H., Antoku, S., Abe, M., Mifune, M. and Togane, M. (2010) High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrology Dialysis Transplantation, 25, 1161-1167. http://dx.doi.org/10.1093/ndt/gfp579
[27] Ito, H., Oshikiri, K., Mifune, M., Abe, M., Antoku, S., Takeuchi, Y., Togane, M. and Yukawa, C. (2012) The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 26, 286-290. http://dx.doi.org/ 10.1016/j.jdiacomp. 2012.04.011
[28] Ito, H., Abe, M., Mifune, M, Oshikiri, K., Antoku, S., Takeuchi, Y. and Togane, M. (2011) Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One, 6, e2781. http://dx.doi.org/10.1371/journal.pone.0027817
[29] Ito, H., Takeuchi, Y., Ishida, H., Otawa, A., Shibayama, A. Antoku, S. Abe, M., Mifune, M. and Togane, M. (2010) Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 1, 273-278. http://dx.doi.org/10.1111/ j.2040-1124.2010.00060.x
[30] Williams, D.T., Harding, K.G. and Price, P. (2005) An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. Diabetes Care, 28, 2206-2210. http://dx.doi.org/10.2337/diacare. 28.9.2206
[31] Alnaeb, M.E., Crabtree, V.P., Boutin, A., Mikhailidis, D.P., Seifalian, A.M. and Hamilton, G. (2007) Prospective assessment of lower-extremity peripheral arterial disease in diabetic patients using a novel automated optical device. Angiology, 58, 579-585. http://dx.doi.org/10.1177/ 0003319707305685

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.